Q1 Earnings Estimate for SLDB Issued By Leerink Partnrs

2025-04-26T05:49:06Z

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Solid Biosciences in a report issued on Monday, April 21st. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS and FY2026 earnings at ($1.94) EPS.

Get Solid Biosciences alerts:

Several other research analysts have also recently issued reports on SLDB. HC Wainwright upped their price target on Solid Biosciences from $16.00 to $20.00 and gave the company a “buy” rating in a report on Monday, March 10th. Chardan Capital reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Friday, March 7th. JPMorgan Chase & Co. decreased their price target on Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, March 13th. Finally, Truist Financial started coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price target on the stock. Eight analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, Solid Biosciences currently has a consensus rating of “Buy” and a consensus price target of $15.67.

Solid Biosciences Price Performance

NASDAQ SLDB opened at $3.30 on Thursday. Solid Biosciences has a 12 month low of $2.45 and a 12 month high of $10.99. The company has a market capitalization of $255.73 million, a P/E ratio of -1.09 and a beta of 2.07. The company’s 50 day simple moving average is $4.24 and its 200 day simple moving average is $4.52.

Institutional Trading of Solid Biosciences

Several institutional investors have recently made changes to their positions in SLDB. China Universal Asset Management Co. Ltd. purchased a new stake in Solid Biosciences in the 4th quarter worth approximately $34,000. Corton Capital Inc. acquired a new position in shares of Solid Biosciences in the fourth quarter worth $41,000. Invesco Ltd. purchased a new stake in shares of Solid Biosciences during the fourth quarter worth $49,000. Sei Investments Co. purchased a new stake in shares of Solid Biosciences during the fourth quarter worth $52,000. Finally, Wells Fargo & Company MN boosted its position in Solid Biosciences by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock valued at $53,000 after purchasing an additional 2,986 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

(Get Free Report)

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.